Squamous-Cell Carcinoma n(%) | Adenocarcinoma n(%) | p-value | |
---|---|---|---|
n = 1154 (89.4) | n = 137 (10.6) | ||
Age, median (range) | 51 (19–87) | 47 (26–78) | 0.023 |
BMI median (range) | 27 (16.1–56.7) | 26.9 (17.5–41.7) | 0.73 |
Performance statusa | 0.11 | ||
< 80% | 166 (14.4) | 11 (8.0) | |
90–100% | 983 (85.2) | 125 (91.2) | |
Unknown | 5 (0.4) | 1 (0.7) | |
FIGO Clinical Stage | < 0.001 | ||
IB2 | 83 (7.2) | 24 (17.5) | |
IIA | 63 (5.5) | 3 (2.2) | |
IIB | 650 (56.3) | 94 (68.6) | |
III | 332 (28.8) | 14 (10.2) | |
IVA | 26 (2.3) | 2 (1.5) | |
Tumor size, cm | 0.36 | ||
< 4 cm | 348 (30.2) | 49 (35.8) | |
> 4 cm | 804 (69.7) | 88 (64.2) | |
Unknown | 2 (0.2) | 0 | |
Parametrial involvement | < 0.001 | ||
Negative | 152 (13.2) | 27 (19.7) | |
Positive but not up to the pelvic wall | 711 (61.6) | 96 (70.1) | |
Extension to the pelvic wall | 291 (25.2) | 14 (10.2) | |
Pelvic Lymph-Node Status | 0.30 | ||
Positive | 402 (34.8) | 43 (31.4) | |
Negative | 692 (60.0) | 90 (65.7) | |
Unknown | 60 (5.2) | 4 (2.9) | |
Tumor Grade | < 0.001 | ||
1 (well differentiated) | 9 (0.8) | 32 (23.4) | |
2 (moderately differentiated) | 861 (74.6) | 87 (63.5) | |
3 (poorly/undifferentiated) | 284 (24.6) | 18 (13.1) | |
LVSI b | 0.002 | ||
Yes | 130 (11.5) | 4 (2.9) | |
No | 1024 (88.7) | 133 (97.1) | |
Treatment outcome | 0.87 | ||
Complete response | 933 (80.8) | 113 (82.5) | |
Partial, progression or stable disease | 199 (17.2) | 22 (16.1) | |
Unknown | 22 (1.9) | 2 (1.5) | |
Total Recurrence during follow-up | n = 933 | n = 113 | 0.61 |
279 (29.9) | 36 (31.9) |